Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction

• Published in: Current opinion in investigational drugs (London, England : 2000) Vol. 9; no. 1; p. 47
• Main Authors: Cincotta, Stephaine L, Yorek, Matthew S, Moschak, Travis M, Lewis, Samantha R, Rodefer, Joshua S
• Format: Journal Article
• Language: English
• Published: England 01-01-2008
• Subjects: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease - drug therapy; Alzheimer Disease - psychology; Animals; Behavior, Animal - drug effects; Cognition Disorders - drug therapy; Humans; Nicotinic Agonists - pharmacology; Nicotinic Agonists - therapeutic use; Receptors, Nicotinic - physiology; Schizophrenia - drug therapy; Schizophrenic Psychology
• ISSN: 1472-4472

Cognitive impairment is one of the most functionally debilitating aspects of neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer's disease, despite treatment with available pharmacotherapies. There is emerging evidence that nicotine improves cognitive function in humans and nonhuman species and this has sparked interest in the development of novel nicotinic treatments for cognitive dysfunction. The examination of selective alpha7 and alpha4beta2 nicotinic acetylcholine receptor (nAChR) agonists suggests that both receptor subtypes mediate improvement in attention, learning and working memory. When compared with available pharmacotherapies, specific nAChR agonists may represent unique targets for the treatment of neuropsychiatric and neurodegenerative disorders that feature cognitive impairment as a key symptom.